IL98425A - Pharmacological preparations for the treatment of rejection of organ transplants, which contain the result of a converted quinoline - Google Patents

Pharmacological preparations for the treatment of rejection of organ transplants, which contain the result of a converted quinoline

Info

Publication number
IL98425A
IL98425A IL9842591A IL9842591A IL98425A IL 98425 A IL98425 A IL 98425A IL 9842591 A IL9842591 A IL 9842591A IL 9842591 A IL9842591 A IL 9842591A IL 98425 A IL98425 A IL 98425A
Authority
IL
Israel
Prior art keywords
composition
quinoline
carboxylic acid
combination
carbon atoms
Prior art date
Application number
IL9842591A
Other languages
English (en)
Hebrew (he)
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of IL98425A publication Critical patent/IL98425A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL9842591A 1990-06-11 1991-06-10 Pharmacological preparations for the treatment of rejection of organ transplants, which contain the result of a converted quinoline IL98425A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/535,672 US5204329A (en) 1990-06-11 1990-06-11 Treatment of organ transplantation rejection

Publications (1)

Publication Number Publication Date
IL98425A true IL98425A (en) 1995-06-29

Family

ID=24135268

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9842591A IL98425A (en) 1990-06-11 1991-06-10 Pharmacological preparations for the treatment of rejection of organ transplants, which contain the result of a converted quinoline

Country Status (14)

Country Link
US (1) US5204329A (ko)
EP (1) EP0537191B1 (ko)
JP (1) JPH05507697A (ko)
KR (1) KR930700107A (ko)
AT (1) ATE165511T1 (ko)
AU (1) AU664354B2 (ko)
CA (1) CA2085002A1 (ko)
DE (1) DE69129332T2 (ko)
DK (1) DK0537191T3 (ko)
ES (1) ES2114888T3 (ko)
IE (1) IE911962A1 (ko)
IL (1) IL98425A (ko)
WO (1) WO1991019498A1 (ko)
ZA (1) ZA914456B (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06116151A (ja) * 1991-08-06 1994-04-26 Asahi Chem Ind Co Ltd 増殖性皮膚疾患治療用組成物
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) * 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
US5409886A (en) * 1993-02-18 1995-04-25 Mitsui Toatsu Chemicals, Incorporated 3-pyrroline-2-one derivatives and herbicidal compositions containing same
US6171585B1 (en) 1993-05-14 2001-01-09 Cedars-Sinai Medical Center IVIg immunosuppression in HLA-sensitized transplant recipients
US20020068057A1 (en) * 1994-03-10 2002-06-06 Marc Feldmann Treatment of autoimmune and inflammatory disorders
US5578609A (en) * 1994-03-25 1996-11-26 The Dupont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
US5627193A (en) * 1995-02-09 1997-05-06 Mitsui Toatsu Chemicals, Inc. Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds
AU2896097A (en) * 1996-05-10 1997-12-05 Novartis Ag Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6376670B1 (en) 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
KR20010014030A (ko) 1997-06-19 2001-02-26 더글라스이.리디치 퀴놀린-인돌 항균제, 이들의 용도 및 조성물
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
UA65587C2 (en) 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
WO1999038846A1 (en) * 1998-01-30 1999-08-05 Procept, Inc. Immunosuppressive agents
TW581681B (en) * 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
US6608045B2 (en) * 1998-03-27 2003-08-19 Chong Kun Dang Corporation Streptomyces sp producing tautomycetin and immunosuppressant comprising tautomycetin as active ingredient
US7323471B1 (en) 1999-08-13 2008-01-29 Dor Biopharma, Inc. Topical azathioprine for the treatment of oral autoimmune diseases
AU2014352920A1 (en) 2013-11-22 2016-06-23 Genzyme Corporation Novel methods for treating neurodegenerative diseases
RU2021128797A (ru) * 2014-02-07 2021-11-26 Ньюрокрайн Байосайенсиз, Инк. Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
US11406707B2 (en) * 2014-02-10 2022-08-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 phosphorylation during graft-versus-host disease
AU2016343633B2 (en) 2015-10-30 2021-07-01 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
WO2017112857A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE)
MX2020003462A (es) 2017-01-27 2020-08-03 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
MX2020002841A (es) 2017-09-21 2020-07-22 Neurocrine Biosciences Inc Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma.
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
KR20200066661A (ko) 2017-10-10 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
EP3836926A4 (en) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6592M (ko) * 1967-10-31 1968-12-30
GB1334705A (en) * 1970-06-19 1973-10-24 Ici Ltd Pharmaceutical compositions containing kynurenic acid derivatives
CH576447A5 (ko) * 1972-03-10 1976-06-15 Ciba Geigy Ag
DE2449030A1 (de) * 1974-10-11 1976-05-20 Schering Ag Neue pyridin-derivate
US4407803A (en) * 1981-08-17 1983-10-04 Abbott Laboratories Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
FI75308C (sv) * 1985-01-25 1988-06-09 Ky Carlson Project Kb Hydrostatiskt drivsystem.
US4625034A (en) * 1985-02-04 1986-11-25 Usv Pharmaceutical Corp. 1,2-Dihydro; 1,2,3,4-tetrahydro; 5,8 dihydro; and 5,6,7,8-tetrahydroquinoline derivatives
US4661499A (en) * 1985-06-18 1987-04-28 Merck Frosst Canada, Inc. 2-[(substituted)-phenoxymethyl]quinolines
GB8602372D0 (en) * 1986-01-31 1986-03-05 Sandoz Ltd Organic compounds
US4851409A (en) * 1986-02-14 1989-07-25 Merck Frosst Canada Inc. 2-substituted quinoline dioic acids and pharmaceutical compositions
US4847381A (en) * 1987-08-31 1989-07-11 American Cyanamid Company 2-Phenyl-4-quinoline carboxylic acids
US4968701A (en) * 1988-04-26 1990-11-06 E. I. Du Pont De Nemours And Company 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
US4861783A (en) * 1988-04-26 1989-08-29 E. I. Du Pont De Nemours And Company 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases
DE3814504A1 (de) * 1988-04-29 1989-11-09 Bayer Ag (alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln

Also Published As

Publication number Publication date
CA2085002A1 (en) 1991-12-12
JPH05507697A (ja) 1993-11-04
WO1991019498A1 (en) 1991-12-26
EP0537191A1 (en) 1993-04-21
DE69129332T2 (de) 1998-08-27
ES2114888T3 (es) 1998-06-16
KR930700107A (ko) 1993-03-13
EP0537191B1 (en) 1998-04-29
ATE165511T1 (de) 1998-05-15
AU664354B2 (en) 1995-11-16
DE69129332D1 (de) 1998-06-04
ZA914456B (en) 1993-02-24
IE911962A1 (en) 1991-12-18
DK0537191T3 (da) 1998-10-07
AU8087391A (en) 1992-01-07
EP0537191A4 (en) 1993-08-11
US5204329A (en) 1993-04-20

Similar Documents

Publication Publication Date Title
IL98425A (en) Pharmacological preparations for the treatment of rejection of organ transplants, which contain the result of a converted quinoline
EP0533280B2 (en) Novel medical use for tachykinin antagonists
AU704955B2 (en) Use of CGMP-phosphodiesterase inhibitors to treat impotence
US5190753A (en) 3-phenyl-5,6-dihydrobenziciacridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5190972A (en) Method of combatting cyclosporine organ toxicity with prostaglandin analogs
AU8412091A (en) Immunosuppressive compositions
EP0534907B1 (en) The use of furanone derivatives for the prevention or treatment of autoimmune diseases
CA2362918A1 (en) Methods and compositions for treating erectile dysfunction
Kay Immunosuppressive agents in chronic severe asthma
CA2417677A1 (en) Medicaments containing cilansetron for treating non-obstipated male ibs patients
Emre et al. Beneficial effect of thalidomide and ciclosporin combination in heterotopic cardiac transplantation in rats
JPH05504550A (ja) 免疫抑制剤として有用なピリミジン生合成インヒビター
KR100681626B1 (ko) 과다 반응성 염증 질환 및 자가면역질환의 치료를 위한 15-디옥시스페르구알린의 용도
US20060079513A1 (en) Methods and compositions including methscopolamine nitrate
CN102614180A (zh) 伊曲康唑在制备治疗多发性骨髓瘤药物中的应用
EP0372541A1 (en) Method for imparting immunosuppression
NL8700191A (nl) Immunosuppressieve middelen, farmaceutische preparaten die ze bevatten en het toepassen van deze middelen.
AU2004260624A1 (en) Use of 3,7-diazabicyclo`3, 3,1 !nonane compounds for the treatment and/or prophylaxis of anti-arrhythmic events in male human patients
CZ2001150A3 (cs) Lék pro léčbu psychóz nebo jiných neuropsychiatrických příznaků u pacientů s Alzheimerovou chorobou
JPH09500646A (ja) アザスピランによるｈｉｖの治療法
EP3355891B1 (en) Pacritinib for use in treating transplant rejection
JP2800412B2 (ja) 免疫抑制作用増強剤
CN112274511A (zh) 用于治疗移植物抗宿主病的喹啉衍生物
JPH0624978A (ja) 抗アレルギー剤
IE912825A1 (en) Immunosuppressive compositions

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees